Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

CoreWeave Stock Slide Sparks Fresh AI Bubble Fears as Debt, Data Center Delays, and Chip Depreciation Take Center Stage

CoreWeave Stock Slide Sparks Fresh AI Bubble Fears as Debt, Data Center Delays, and Chip Depreciation Take Center Stage

On December 16, 2025, CoreWeave’s sharp selloff became a lightning rod for a broader market debate: is the AI infrastructure boom entering its most fragile phase, where execution hiccups and financing costs matter more than hype? New reporting and market commentary today highlights a mix of catalysts—construction delays at a key Texas data center tied to OpenAI, worries about debt-heavy growth, and a rising chorus of skeptics questioning whether the economics of renting cutting-edge Nvidia GPUs can hold up as hardware ages fast and capital gets more expensive. The Wall Street Journal+1
16 December 2025
······
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma
16 December 2025
···
Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

December 16, 2025 — Inspire Veterinary Partners, Inc. is once again on traders’ radar, but not for the comforting reasons investors typically like in a healthcare-services name. The stock is trading around $0.05 per share in early Tuesday action, after a stretch of extreme volatility driven by Nasdaq listing risk, capital-structure changes, and a growing conversation around potential dilution. Investing.com
16 December 2025
·
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin. The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1
16 December 2025
··
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following a strong after-hours move the prior session. StockAnalysis+1
16 December 2025
··
Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

December 16, 2025 — Affirm Holdings, Inc. heads into today with investors watching two forces that can move buy-now-pay-later stocks fast: company messaging and policy risk. Shares closed Monday, Dec. 15 at $65.66, down 2.36% on the day, setting the stage for today’s investor-focused event featuring the company’s CFO. StockAnalysis
16 December 2025
·
Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

SINGAPORE — December 16, 2025. Singapore’s bank-heavy equity market delivered a fresh headline on Tuesday: DBS and OCBC both notched new all-time highs, reinforcing a late‑2025 narrative that the “big three” banks remain core holdings for income-focused investors—just as the debate shifts to whether the rally can hold into 2026. The Business Times
16 December 2025
···
Tesla Stock (TSLA) Surges on Driverless Robotaxi Tests: Latest News, Analyst Forecasts, and Key Risks for December 16, 2025

Tesla Stock (TSLA) Surges on Driverless Robotaxi Tests: Latest News, Analyst Forecasts, and Key Risks for December 16, 2025

Tesla, Inc. is back at the center of the market conversation on December 16, 2025, after a fresh burst of optimism around the company’s autonomous-driving ambitions pushed shares higher. Tesla stock was trading around $475, up roughly 3.5%, and sitting near the top of its 52‑week range. Investing.com
16 December 2025
···
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome, Inc. is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a biotech stock in opposite directions at the same time. On the one hand: a clear late-stage efficacy win that supports an FDA filing. On the other: a proposed $400 million common stock offering that introduces near-term dilution risk. Reuters+2Immunome Investors+2
16 December 2025
··
1 … 466 467 468 469 470 … 609
Follow on Google News
Add as preferred source Open in Google News